Seeking Alpha

MELA Sciences, Inc. (MELA)

  • Mon, Feb. 23, 12:44 PM
    | Comment!
  • Thu, Feb. 19, 12:46 PM
    | 1 Comment
  • Thu, Feb. 19, 10:44 AM
    • "Small is better" appears to be the recent investment theme in healthcare stocks. Thinly-traded nano cap MELA Sciences (MELA +42.4%) jumps on a 12x surge in volume on no particular news. Shares are up 63% since Tuesday.
    • Other recent nano/micro cap bullish moves: (CLRX +102.6%)(TTPH +8.2%)(AKAO +3.7%)(ROSG +1.8%)(HTBX -3.7%)(EGRX +3.7%)(ONCY -12%)(GENE -5%)(WGBS -5.6%)(SGNL -4.2%)
  • Fri, Jan. 2, 12:50 PM
    | Comment!
  • Fri, Jan. 2, 11:45 AM
    • Thinly-traded nano cap Mela Sciences (MELA +25%) spikes on a 5x surge in volume albeit on turnover of only ~330K shares. No news accounts for the move other than the early money flow into biotech.
    • The company makes a melanoma detection device called MelaFind.
    | Comment!
  • Oct. 21, 2014, 1:32 PM
    • Thinly-traded nano cap Mela Sciences (MELA +19.5%) rises on a 4x surge in volume albeit on turnover of only 135K shares.
    • Yesterday, the SEC declared its S-3 effective. It issued its prospectus today for the sale of up to 21,637,429 shares of common stock by selling stockholders. The July 21, 2014 securities purchase agreement included warrants to purchase up to 10,643,276 shares of common stock at $2.45. This is the only potential source of new capital available to the company. MELA currently exchanges hands for ~$2.21.
    • The company's cash balance as of June 30, 2014 was $4.2M. Its cash burn rate is ~$5M per quarter.
    | Comment!
  • Oct. 21, 2014, 12:46 PM
    | Comment!
  • Jul. 22, 2014, 12:47 PM
  • Aug. 7, 2013, 6:15 PM
    • MELA Sciences (MELA): Q2 EPS of -$0.17 in-line.
    • Revenue of $144.4K misses by $105.6K. (PR)
  • Jun. 24, 2013, 1:19 PM
    MELA Sciences (MELA +5.6%) gets a pop after Interim CEO Robert Coradini disclosed the purchase of 50K shares today at an average price of $0.7198, bringing his stake to 71,457 shares. Director Kathryn Swintek also purchased 17K shares at $0.729.
    | Comment!
  • Jun. 5, 2013, 8:24 PM
    MELA Sciences (MELA) files a $75 million mixed securities shelf with the SEC. Shares -19% AH.
    | Comment!
  • May. 1, 2013, 3:46 PM
    Mela Sciences (MELA -10.6%) takes a hit today after its Q1 revenue misses by a huge margin despite a nearly 12-fold increase over year-ago levels. Revenue for the three months ended March 31 totaled $144,100, up from $11,250 during the same quarter last year but still lagging the analyst consensus by more than 76%, as a sizeable chunk of the quarters revenue from Melafind sales were deferred.
  • Mar. 6, 2013, 3:18 PM
    Mela Sciences (MELA -17%) reverses yesterday's post-session gains and sinks on a disappointing Q4. Higher marketing expenses, coupled with an increase in costs associated with installing its Melafinds systems in medical offices, all conspired to pressure margins.
    | Comment!
  • Mar. 5, 2013, 6:47 PM
    More on Mela Sciences (MELA): Q4 comes in line with estimates. Net loss for quarter was $6.1M, or $0.19 per diluted share, compared to a net loss of $4.5M, or $0.17 per diluted share for Q411. The higher net losses can be attributed to greater SG&A costs, and an increase in direct costs associated with the placement of MelaFind systems in dermatologists' offices. Total revenues were boosted by increased installation of its MelaFind, with 20 additional user agreements signed in Q4. Shares +4.2% AH.
    | Comment!
  • Feb. 12, 2013, 4:06 PM
    MELA Sciences (MELA -13%) finishes lower today after pricing its 6.1M share public offering at $1.30 per share, a 23% discount to yesterdays close. The company plans to use the funds for its commercial launch of MelaFind.
    | Comment!
  • Feb. 12, 2013, 12:45 PM
    Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
    Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%.
    | Comment!
Visit Seeking Alpha's
MELA vs. ETF Alternatives
Company Description
Mela Sciences Inc is a medical device company focused on the commercialization of its flagship product, MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid in the detection of melanoma.